Nutrição mineral de seringueira XII. Quantidade de Al no substrato afetando a concentração e o acúmulo de Ca, Mg e S em seringueira (Hevea spp)

Com o propósito de comparar os efeitos de doses crescentes de alumínio sobre a concentração e acúmulo de Ca, Mg e S sobre a planta conduziu-se o experimento usando-se separadamente a solução nutritiva de BOLLE JONES (1957) e soluções de alumínio nas concentrações de 0, 5, 10, 15, 20 e 25 ppm em que as plantas passaram 24 horas e outras 24 horas em solução sem alumínio. Noventa dias após as plantas foram coletadas e separadas em raiz, caule, folhas dos verticilos inferiores e folhas do último verticilo. Determinou-se as concentrações e os acúmulos de Ca, Mg, e S. Os autores concluíram que níveis superiores a 15ppm de alumínio na solução provocam distúrbios nutricionais destes elementos em Hevea.

Riqueza de formigas (Hymenoptera, Formicidae) da serapilheira em fragmentos de floresta semidecídua da Mata Atlântica na região do Alto do Rio Grande, MG, Brasil

As comunidades de Formicidae (Insecta, Hymenoptera) foram estudadas em fragmentos de floresta semidecídua inseridos no bioma Mata Atlântica medindo de 2,99 a 45,5 ha na região do Alto do Rio Grande, Minas Gerais, Brasil. As formigas foram coletadas em 15 amostras de serapilheira de 1 m² em cada fragmento, usando o método de extrator de Winkler. Cada amostra teve distância mínima de 50 m uma da outra. Um total de 142 espécies de formigas foi distribuído entre 40 gêneros, 23 tribos e 10 subfamílias. As comunidades amostradas mostraram uma alta riqueza e altos valores no índice de diversidade. O tamanho da área dos fragmentos não influenciou na riqueza de espécies de formigas.

Estudo sôbre a esporulação de uma amostra de Bacillus: II - Importância dos íons Mn e Mg na indução do processo

Foi verificado que a esporogênese de B. licheniformis, amostra 23910, sòmente ocorre quando Mn[2+] ou Mg[2+] etão presentes, em meio sintético, nas concentrações de 0,1 mg%. Ambos os íons estimulam o crescimento, e no 14º dia de incubação a cultura apresenta endósporos e esporos livres, quando a concentração dos metais é de 0,1 mg%. Aumentando-se o teor dêstes íons para 1,0 mg%, esporos livres são obtidos no 10º dia de incubação. Outros íons testados como, Ca[2+], Fe[2+], Co[2+], Cu[2+], Mo[6+], Zn[2+] e B[3+] não mostraram influir no processo. Co[2+] e Cu[2+] foram tóxicos, inibindo o crescimento. O Ca[2+] pareceu não interferir na esporogênese, mas foi capaz de inibir o cresciemnto na concentração de 3mg%. O aparecimento de endósporos e esporos livres, no meio, quando Mn[2+] encontra-se a 1,0 mg%, coincide com um teor de glicose correspontente a cêrca de 12,5% da concentração inicial do açúcar. O autor sugere, também, a possibilidade do Mn[2+] ou Mg[2+] ativar a síntese do ácido dipicolínico.

Millora de la rendibilitat del perer (cv. Conference) mitjançant la intensificació del conreu

Tot i que el sistemes de plantació d’alta densitat en pomera i perera s’han desenvolupat considerablement en altres països, en l’àmbit de Catalunya i més concretament a la zona fruitera de Lleida, no es disposa de cap referència del seu comportament, cosa què no coincideix amb l’interès creixent del sector productor pel conreu de la perera i per la millora de la seva rendibilitat. Amb aquesta experiència es pretén cobrir el buit d’informació que hi ha referent a la tecnologia de producció de la perera i específicament pel que fa referència a la utilització de plantacions intensives o d’alta densitat de plantació amb portaempelts nanisants. L’objectiu de l’assaig és avaluar diferents sistemes de plantació que permetin incrementar la rendibilitat del conreu de la perera, millorant el balanç econòmic ingressos/despeses, mitjançant la intensificació del conreu que ha de permetre una major rapidesa d’entrada en producció i una disminució del costos de producció, però no d’implantació. Per això, s’avaluaran 5 densitats de plantació, una de les quals és el Fus que s’ha elegit com a testimoni de referència, ja que és utilitzat habitualment a la zona. Es descriu a continuació la metodologia utilitzada i s’exposen els resultats obtinguts l’any 2000, que correspon al segon verd i que fan referència principalment als costos de plantació, costos de ma d’obra, produccions i paràmetres de qualitat dels fruits.

Morbidade da doença de Chagas: III. Estudo longitudinal, de seis anos, em Virgem da Lapa, MG, Brasil

Um estudo longitudinal clínico, radiológico e eletrocardiográfico do tipo caso-controle realizado no município de Virgem da Lapa, Minas Gerais, Brasil, com o acompanhamento de 124 chagásicos crônicos durante seis anos, revelou que 62,1% dos pacientes permaneceram com o quadro inicial inalterado, a maioria deles na forma indeterminada, 32,3% evoluíram com progressão da doença e 5,6% tiveram normalização do eletrocardiograma. Os resultados mencionados, quando comparados aos obtidos no grupo controle composto de pares não chagásicos da mesma idade e sexo, demonstraram uma progressão de 27,4% maior entre os pacientes com sorologia positiva, o que representa o excesso de risco ou componente exclusivamente chagásico na evolução da doença. Não houve diferença de progressão da doença em relação ao sexo, porém ela foi mais precoce e sete vezes mais freqüente em relação à cardiopatia do que ao megaesôfago, ambas ocorrendo na maioria das vezes em grau leve ou moderada. Em 192 chagásicos e 188 não chagásicos observados na área, no referido período, houve uma mortalidade 3,6 vezes maior entre os chagásicos, com uma letalidade pela cardiopatia de 8,9%, sem diferença entre os sexos, porém mais precoce no sexo masculino. A morte súbita foi mais freqüente do que a morte por insuficiência cardíaca. O prognóstico foi bom para os pacientes da forma indeterminada e digestiva e reservado para os casos de cardiopatia, principalmente os de graus mais elevados.

Phosphodiesterase-5 inhibition mimics intermittent reoxygenation and improves cardioprotection in the hypoxic myocardium.

Although chronic hypoxia is a claimed myocardial risk factor reducing tolerance to ischemia/reperfusion (I/R), intermittent reoxygenation has beneficial effects and enhances heart tolerance to I/R. AIM OF THE STUDY: To test the hypothesis that, by mimicking intermittent reoxygenation, selective inhibition of phosphodiesterase-5 activity improves ischemia tolerance during hypoxia. Adult male Sprague-Dawley rats were exposed to hypoxia for 15 days (10% O₂) and treated with placebo, sildenafil (1.4 mg/kg/day, i. p.), intermittent reoxygenation (1 h/day exposure to room air) or both. Controls were normoxic hearts. To assess tolerance to I/R all hearts were subjected to 30-min regional ischemia by left anterior descending coronary artery ligation followed by 3 h-reperfusion. Whereas hypoxia depressed tolerance to I/R, both sildenafil and intermittent reoxygenation reduced the infarct size without exhibiting cumulative effects. The changes in myocardial cGMP, apoptosis (DNA fragmentation), caspase-3 activity (alternative marker for cardiomyocyte apoptosis), eNOS phosphorylation and Akt activity paralleled the changes in cardioprotection. However, the level of plasma nitrates and nitrites was higher in the sildenafil+intermittent reoxygenation than sildenafil and intermittent reoxygenation groups, whereas total eNOS and Akt proteins were unchanged throughout. CONCLUSIONS: Sildenafil administration has the potential to mimic the cardioprotective effects led by intermittent reoxygenation, thereby opening the possibility to treat patients unable to be reoxygenated through a pharmacological modulation of NO-dependent mechanisms.

Infecção natural das glândulas anais de gambás (Didelphis albiventris) pelo Trypanosoma cruzi no município de Bambuí - MG

De 87 gambás, Didelphis albiventris, capturados na região de Bambuí (MG), 32 (36,7%) estavam infectados pelo Trypanosoma cruzi. Os índices de infecção foram 34,9%, 81,8% e 7,7%, respectivamente, para animais capturados em ambiente silvestre, peridomiciliar rural e periodomiciliar urbano. Em 20 gambás infectados as glândulas anais foram examinadas repetidamente e apenas um (5%) animal (GA09) apresentou exame positivo. Foram positivos 7 dos 17 exames a fresco da secreção glandular desta animal ao longo de 18 meses. Material destas glândulas produziu parasitemia patente em gambás e infecção subpatente em camundongos. A análise isoenzimática realizada com amostras de T. cruzi do GA09, obtidas via hemocultura, xenodiagnóstico e glândulas anais demonstraram pertencerem rigorosamente ao mesmo Zimodema semelhante ao Zimodema Z1. As observações mostram que a infecção das glândulas anias pelo T. cruzi em gambás naturalmente infectados da região de Bambuí é baixa.

Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.

BACKGROUND: Recommended oral voriconazole (VRC) doses are lower than intravenous doses. Because plasma concentrations impact efficacy and safety of therapy, optimizing individual drug exposure may improve these outcomes. METHODS: A population pharmacokinetic analysis (NONMEM) was performed on 505 plasma concentration measurements involving 55 patients with invasive mycoses who received recommended VRC doses. RESULTS: A 1-compartment model with first-order absorption and elimination best fitted the data. VRC clearance was 5.2 L/h, the volume of distribution was 92 L, the absorption rate constant was 1.1 hour(-1), and oral bioavailability was 0.63. Severe cholestasis decreased VRC elimination by 52%. A large interpatient variability was observed on clearance (coefficient of variation [CV], 40%) and bioavailability (CV 84%), and an interoccasion variability was observed on bioavailability (CV, 93%). Lack of response to therapy occurred in 12 of 55 patients (22%), and grade 3 neurotoxicity occurred in 5 of 55 patients (9%). A logistic multivariate regression analysis revealed an independent association between VRC trough concentrations and probability of response or neurotoxicity by identifying a therapeutic range of 1.5 mg/L (>85% probability of response) to 4.5 mg/L (<15% probability of neurotoxicity). Population-based simulations with the recommended 200 mg oral or 300 mg intravenous twice-daily regimens predicted probabilities of 49% and 87%, respectively, for achievement of 1.5 mg/L and of 8% and 37%, respectively, for achievement of 4.5 mg/L. With 300-400 mg twice-daily oral doses and 200-300 mg twice-daily intravenous doses, the predicted probabilities of achieving the lower target concentration were 68%-78% for the oral regimen and 70%-87% for the intravenous regimen, and the predicted probabilities of achieving the upper target concentration were 19%-29% for the oral regimen and 18%-37% for the intravenous regimen. CONCLUSIONS: Higher oral than intravenous VRC doses, followed by individualized adjustments based on measured plasma concentrations, improve achievement of the therapeutic target that maximizes the probability of therapeutic response and minimizes the probability of neurotoxicity. These findings challenge dose recommendations for VRC.

Ganciclovir Exposure under a 450 mg Daily Dosage of Valganciclovir for the Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients.

Background: It is suggested that a low dose of valganciclovir can be equally effective than a standard dose for cytomegalovirus (CMV) prophylaxis after kidney transplantation. The aim of our study was to determine the ganciclovir exposure observed under a routine daily dosage of 450 mg valganciclovir in kidney transplant recipients with a wide range of renal function. Methods: In this prospective study, kidney transplant recipients with a GFR MDRD above 25 mL/min at risk for CMV (donor or recipient seropositive for CMV) received a dose of valganciclovir (450 mg daily) prophylaxis for 3 months. Ganciclovir levels at trough (Ctrough) and at peak (C3h) were measured monthly. Ganciclovir exposure (AUC0-24) was estimated using Bayesian non-linear mixed-effect modelling (NONMEM) and compared between 3 groups of patients according to their kidney function: GFRMDRD 26-39 mL/min (Group 1), GFRMDRD 40-59 mL/min (Group 2) and GFRMDRD 60-90 mL/min (Group 3). CMV DNAemia was assessed during and after prophylaxis using PCR. Results: Thirty-six patients received 450 mg daily of valganciclovir for 3 months. Median ganciclovir C3h was 3.9 mg/L (range: 1.3-7.1) and Ctrough was 0.4 mg/L (range 0.1-2.7). Median (range) AUC0-24 of ganciclovir was 59.3 mg.h/L (39.0-85.3) in Group 1 patients, 35.8 mg.h/L (24.9-55.8) in Group 2 patients and 29.6 mg.h/L (22.0- 43.2) in Group 3 patients (p<0.001). Anemia was more common in Group 1 patients compared to patients on the other groups (p=0.01). No differences in other adverse events according to ganciclovir exposure were observed. CMV DNAemia was not detected during prophylaxis. After discontinuing prophylaxis, CMV DNAemia was seen in 8/34 patients (23.5%) and 4/36 patients (11%) developed CMV disease. Conclusion: A routine dosage of valganciclovir achieved plasma levels of ganciclovir in patients with GFR>60 mL/min similar to those previously reported using oral ganciclovir. A daily dose of 450 mg valganciclovir appears to be acceptable for CMV prophylaxis in most kidney transplant recipients.

Pulmonary biology of anti-interleukin 5 antibodies

Interleukin 5 (IL-5) is a critical cytokine for the maturation of eosinophil precursors to eosinophils in the bone marrow and those eosinophils then accumulate in the lungs during asthma. We have studied anti IL-5 antibodies on allergic responses in mice, guinea pigs and monkeys and are extending this experiment into humans with a humanized antibody. In a monkey model of pulmonary inflammation and airway hyperreactivity, we found that the TRFK-5 antibody blocked both responses for three months following a single dose of 0.3 mg/kg, i.v. This antibody also blocked lung eosinophilia in mice by inhibiting release from the bone marrow. To facilitate multiple dosing and to reduce immunogenicity in humans, we prepared Sch 55700, a humanized antibody against IL-5. Sch 55700 was also active against lung eosinophilia in allergic monkeys and mice and against pulmonary eosinophilia and airway hyperresponsiveness in guinea pigs. Furthermore, as opposed to steroids, Sch 55700 did not cause immunosuppression in guinea pigs. Studies with this antibody in humans will be critical to establishing the therapeutic potential of IL-5 inhibition.

5-HT2A and alpha1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants.

Addictive properties of drugs of misuse are generally considered to be mediated by an increased release of dopamine (DA) in the ventral striatum. However, recent experiments indicated an implication of alpha1b-adrenergic receptors in behavioural responses to psychostimulants and opiates. We show now that DA release induced in the ventral striatum by morphine (20 mg/kg) is completely blocked by prazosin (1 mg/kg), an alpha1-adrenergic antagonist. However, morphine-induced increases in DA release in the ventral striatum were found to be similar in mice deleted for the alpha1b-adrenergic receptor (alpha1b-AR KO) and in wild-type (WT) mice, suggesting the presence of a compensatory mechanism. This acute morphine-evoked DA release was completely blocked in alpha1b-AR KO mice by SR46349B (1 mg/kg), a 5-HT2A antagonist. SR46349B also completely blocked, in alpha1b-AR KO mice, the locomotor response and the development of behavioural sensitization to morphine (20 mg/kg) and D-amphetamine (2 mg/kg). Accordingly, the concomitant blockade of 5-HT2A and alpha1b-adrenergic receptors in WT mice entirely blocked acute locomotor responses but also the development of behavioural sensitization to morphine, D-amphetamine or cocaine (10 mg/kg). We observed, nevertheless, that inhibitory effects of each antagonist on locomotor responses to morphine or D-amphetamine were more than additive (160%) in naïve WT mice but not in those sensitized to either drug. Because of these latter data and the possible compensation by 5-HT2A receptors for the genetic deletion of alpha1b-adrenergic receptors, we postulate the existence of a functional link between these receptors, which vanishes during the development of behavioural sensitization.

Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin.

Concentrations of total (R) + (S) and of the enantiomers (R) and (S) of thioridazine and metabolites were measured in 21 patients who were receiving 100 mg thioridazine for 14 days and who were comedicated with moclobemide (450 mg/day). Two patients were poor metabolizers of dextromethorphan and one was a poor metabolizer of mephenytoin. Cytochrome P450IID6 (CYP2D6) is involved in the formation of thioridazine 2-sulfoxide (2-SO) from thioridazine and also probably partially in the formation of thioridazine 5-sulfoxide (5-SO), but not in the formation of thioridazine 2-sulfone (2-SO2) from thioridazine 2-SO. Significant correlations between the mephenytoin enantiomeric ratio and concentrations of thioridazine and metabolites suggest that cytochrome P450IIC19 could contribute to the biotransformation of thioridazine into yet-unknown metabolites, other than thioridazine 2-SO, thioridazine 2-SO2, or thioridazine 5-SO. An enantioselectivity and a large interindividual variability in the metabolism of thioridazine have been shown: measured (R)/(S) ratios of thioridazine, thioridazine 2-SO fast eluting (FE), thioridazine 2-SO slow eluting (SE), thioridazine 2-SO (FE+SE), thioridazine 2-SO2, thioridazine 5-SO(FE), and thioridazine 5-SO(SE) were (mean +/- SD) 3.48 +/- 0 .93 (range, 2.30 to 5.80), 0.45 +/- 0.22 (range, 0.21 to 1.20), 2.27 +/- 8.1 (range, 6.1 to 40.1), 4.64 +/- 0.68 (range, 2.85 to 5.70), 3.26 +/- 0.58 (range, 2.30 to 4.30), 0.049 +/- 0.019 (range, (0.021 to 0.087), and 67.2 +/- 66.2 (range, 16.8 to 248), respectively. CYP2D6 is apparently involved in the formation of (S)-thioridazine 2-SO(FE), (R)-thioridazine 2-SO(SE), and also probably (S)-thioridazine 5-SO(FE) and (R)-thioridazine 5-SO(SE).

Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon Region of Brazil

Since the late 1970s pyrimethamine-sulfadoxine (PS; FansidarTM Hoffman-LaRoche, Basel) has been used as first line therapy for uncomplicated malaria in the Amazon basin. Unfortunately, resistance has developed over the last ten years in many regions of the Amazon and PS is no longer recommended for use in Brazil. In vitro resistance to pyrimethamine and cycloguanil (the active metabolite of proguanil) is caused by specific point mutations in Plasmodium falciparum dihydrofolate reductase (DHFR), and in vitro resistance to sulfadoxine has been associated with mutations in dihydropteroate synthase (DHPS). In association with a proguanil-sulfamethoxazole clinical trial in Brazil, we performed a nested mutation-specific polymerase chain reaction to measure the prevalence of DHFR mutations at codons 50, 51, 59, 108 and 164 and DHPS mutations at codons 436, 437, 540, 581 and 613 at three sites in the Brazilian Amazon. Samples from two isolated towns showed a high degree of homogeneity, with the DHFR Arg-50/Ile-51/Asn-108 and DHPS Gly-437/Glu-540/Gly-581 mutant genotype accounting for all infections in Peixoto de Azevedo (n = 15) and 60% of infections in Apiacás (n = 10), State of Mato Grosso. The remaining infections in Apiacás differed from this predominant genotype only by the addition of the Bolivia repeat at codon 30 and the Leu-164 mutation in DHFR. By contrast, 17 samples from Porto Velho, capital city of the State of Rondônia, with much in- and out-migration, showed a wide variety of DHFR and DHPS genotypes.

Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.

BACKGROUND: Gemcitabine, oxaliplatin and 5-fluorouracil (5-FU) are active in biliary tract cancer and have a potentially synergistic mode of action and non-overlapping toxicity. The objective of these trials was to determine response, survival and toxicity separately in patients with bile duct cancer (BDC) and gallbladder cancer (GBC) treated with gemcitabine/oxaliplatin/5-FU chemotherapy. METHODS: Eligible patients with histologically proven, advanced or metastatic BDC (n=37) or GBC (n=35) were treated with gemcitabine (900 mg m(-2) over 30 min), oxaliplatin (65 mg m(-2)) and 5-FU (1500 mg m(-2) over 24 h) on days 1 and 8 of a 21-day cycle. Tumour response was the primary outcome measure. RESULTS: Response rates were 19% (95% CI: 6-32%) and 23% (95% CI: 9-37%) for BDC and GBC, respectively. Median survivals were 10.0 months (95% CI: 8.6-12.4) and 9.9 months (95% CI: 7.5-12.2) for BDC and GBC, respectively, and 1- and 2-year survival rates were 40 and 23% in BDC and 34 and 6% in GBC (intention-to-treat analysis). Major grade III and IV adverse events were neutropenia, thrombocytopenia, elevated bilirubin and anorexia. CONCLUSION: Triple-drug chemotherapy achieves comparable results for response and survival to previously reported regimens, but with more toxicity.